Replimune Group (NASDAQ:REPL) Shares Up 6% After Analyst Upgrade

Replimune Group, Inc. (NASDAQ:REPL) shares rose 6% on Wednesday after BMO Capital Markets raised their price target on the stock from $18.00 to $27.00. BMO Capital Markets currently has an outperform rating on the stock. Replimune Group traded as high as $12.41 and last traded at $12.57. Approximately 67,909 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 795,967 shares. The stock had previously closed at $11.85.

A number of other brokerages also recently weighed in on REPL. JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright raised their target price on shares of Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $19.14.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC grew its stake in shares of Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock valued at $318,000 after purchasing an additional 3,374 shares during the period. Algert Global LLC grew its stake in shares of Replimune Group by 5.4% during the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after purchasing an additional 4,340 shares during the period. Creative Planning grew its stake in shares of Replimune Group by 28.7% during the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after purchasing an additional 4,699 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock valued at $144,000 after purchasing an additional 5,926 shares during the period. Finally, MetLife Investment Management LLC grew its stake in shares of Replimune Group by 21.5% during the 3rd quarter. MetLife Investment Management LLC now owns 35,134 shares of the company’s stock valued at $385,000 after purchasing an additional 6,216 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Up 9.9 %

The stock has a 50 day simple moving average of $12.18 and a 200-day simple moving average of $11.28. The firm has a market capitalization of $890.83 million, a P/E ratio of -4.27 and a beta of 1.28. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. On average, equities research analysts forecast that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.